Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

← Back to all trials

Recruiting NCT07935109

Management of Severe Plasmodium Falciparum Malaria With Oral Artemisinin Derivatives

Conditions: Malaria, Falciparum, Plasmodium Falciparum, Artemisinins, Antimalarials, Artesunate, Treatment Outcome

Sex: All

Ages: 18 Years – N/A

Healthy volunteers: No

Enrollment: 1000

Sponsor: Centre Hospitalier de Saint-Denis

Location: Centre Hospitalier de Saint-Denis Saint-Denis France

Summary

ACTs could be used as first-line treatment for Plasmodium falciparum malaria without clinical signs of severity but with biological severity criteria. The study aims to determine the real-world frequency of ACT monotherapy use in cases of P. falciparum malaria with severity criteria, and to compare the treatment success of ACTs with that of artesunate.

Eligibility Criteria

Inclusion Criteria * Patients aged 18 years or older. * Diagnosis of Plasmodium falciparum malaria. * At least one clinico-biological criterion of severe malaria. * Hospitalization in a medical intensive care/critical care unit. * Hospitalization between January 1, 2011 and October 30, 2025. Exclusion Criteria * Age \

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07935109). StuddyBuddy aggregates publicly available trial information.